GLO1 and HIV-1 infection: A single intravenous injection of AAV2/9-Endo-Glo1 to hu-mice five weeks after HIV-1 infection, increased myocardial Glo1 protein and attenuated the increase in VAP-1 as observed at seventeen weeks following viral infection (Figure 8D).